A
Asciminib
Subsidy Information and Financing Scheme
Medical Assistance Fund
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Availability of ACE Drug Guidance
Yes
Post-marketing information
Biologics Drug Information Overview
No
Active ingredient: Asciminib
General information
Subsidy Information and Financing Scheme
[MAF] Asciminib Tablet 20 mg, 40 mg
Monotherapy for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase whose disease is resistant and/or who are intolerant to two or more tyrosine kinase inhibitors. Asciminib is not recommended for patients with T315I mutation.
[MSHL] Asciminib Tablets 20 mg, 40 mg
Monotherapy for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase whose disease is resistant and/or who are intolerant to two or more tyrosine kinase inhibitors. Asciminib is not recommended for patients with T315I mutation.
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Asciminib 20 mg and 40 mg tablets as monotherapy for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase whose disease is resistant and/or who are intolerant to two or more tyrosine kinase inhibitors.
Asciminib is not recommended for patients with T315I mutation.
Funding status
[R] Asciminib 20 mg and 40 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 April 2026.
[NR] MAF assistance does not apply to asciminib 100 mg tablet.
Clinical indication, subsidy class and MediShield Life claim limit for asciminib are provided in the Annex.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 20 mg |
|
Tablet 40 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.